Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes mellitus at screening~* Painful distal symmetric polyneuropathy, diagnosed at least 6 months prior to screening (see Procedures manual for the Diagnosis of Diabetic Peripheral Neuropathy and Neurological Examination for details)~Exclusion Criteria:~* HbA1c (National Glycohemoglobin Standardization Program) \> 10.0% at screening~* Uncontrolled blood glucose within 1 month prior to screening, at screening or randomization~* Other severe pain at screening or randomization, unrelated to DPN, that may confound the assessment of DPNP~* Neurologic disorders at screening or randomization, unrelated to DPN, that may confound the assessment of DPNP~* Major psychiatric disorders at screening or randomization~* Creatinine clearance (using the Cockcroft-Gault equation) \< 60 mL/min at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirogabalin (Type: EXPERIMENTAL): Mirogabalin 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (14-weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).